Business Insider
My Markets Watchlist
Markets Stocks

QIAGEN N.V. Stock , QGEN

45.97 +0.49 +1.08%
11:17:59 AM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Monday morning 06/09/2025 the QIAGEN N.V. share started trading at the price of $45.70. Compared to the closing price on Friday 06/06/2025 on BTT of $45.48, this is a gain of 0.48%. There are 216.56 M shares outstanding in QIAGEN N.V., which values the company at $8.08 B.

QIAGEN Stock Snapshot

45.96
Bid
6.00
Bid Size
45.98
Ask
6.00
Ask Size
6/9/2025
Date
11:17 AM
Time
25,602.00
Volume
45.48
Prev. Close
45.70
Open
9.85 B
Market Cap in USD
216.56 M
Number of Shares
216.56 M
Total Number of Shares
45.61
Day Low
46.03
Day High
45.97
37.63
52 Week Low
49.28
52 Week High
45.97
0.00
Dividend in USD
0.00
Dividend Yield
119.71
P/E Ratio
99.21
Free Float in %
0.38
EPS in USD
16.51
Book Value per Share in USD
3.08
Cash Flow per Share in USD

Historical Prices for QIAGEN

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

QIAGEN Analyst Data

Total Analysts: 16
Buy Ratings: 10 Neutral Ratings: 6 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 42.00 Median: 49.31 Highest: 60.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

QIAGEN Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
04/21/25 Baird Patrick & Co
Maintained Hold $43
02/19/25 Baird Patrick & Co
Downgraded to Hold $42
02/07/25 UBS
Maintained Hold $48
06/27/24 Wolfe Research
Upgraded to Buy $50
06/18/24 J.P. Morgan
Maintained Buy $54
05/01/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $45
02/16/24 Morgan Stanley
Upgraded to Buy $51
02/08/24 J.P. Morgan
Maintained Buy $52
02/08/24 Citigroup Corp.
Maintained Buy $60
12/20/23 J.P. Morgan
Maintained Buy $50
12/19/23 Wells Fargo & Co
Maintained Hold $44
12/13/23 Wolfe Research
Maintained Hold
12/07/23 Goldman Sachs
Upgraded to Buy
11/02/23 UBS
Maintained Hold $42
10/17/23 J.P. Morgan
Maintained Buy $50
09/26/23 Citigroup Corp.
Maintained Buy $60
09/12/23 Baird Patrick & Co
Maintained Buy $50
08/09/23 UBS
Maintained Hold $48

QIAGEN Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 2,058 2,181 2,331 2,505 2,719
Dividend 0.09 0.10 0.12 0.20 0.25
Dividend Yield (in %) 0.21 % 0.22 % 0.26 % 0.44 % 0.55 %
EPS 2.34 2.53 2.77 3.00 3.28
P/E Ratio 19.42 18.00 16.44 15.14 13.86
EBIT 622 670 729 801 854
EBITDA 769 830 899 956 1,046
Net Profit 513 548 595 648 731
Net Profit Adjusted 513 548 595 648 731
Pre-Tax Profit 636 684 746 809 910
Pre-Tax Profit Reported 545 608 671 745 832
EPS (Non-GAAP) ex. SOE 2.33 2.44 2.70 - -
EPS (GAAP) 2.04 2.27 2.54 2.78 3.02
Gross Income 1,396 1,492 1,617 1,732 1,835
Cash Flow from Investing -26 -173 -177 -191 -
Cash Flow from Operations 578 692 740 841 -
Cash Flow from Financing -665 -253 -248 -109 -
Cash Flow per Share 2.89 3.18 3.43 3.70 3.66
Free Cash Flow 407 494 538 618 -
Free Cash Flow per Share 1.78 2.28 2.48 2.83 -
Book Value per Share 17.32 19.16 21.01 23.12 25.89
Net Debt 314 -25 -403 -868 -1,148
Research & Development Exp. 187 202 212 227 237
Capital Expenditure 178 178 186 193 181
Selling, General & Admin. Exp. 576 604 634 669 -
Shareholder’s Equity 3,800 4,135 4,487 5,294 5,670
Total Assets 5,499 5,745 6,051 6,916 -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 11 11 18 18
Average Estimate - 0.601 USD 0.583 USD 2.342 USD 2.526 USD
Year Ago - -0.850 USD 0.454 USD 0.386 USD -
Publish Date - 8/12/2025 11/4/2025 - -
Revenue Estimates
No. of Analysts - 12 12 18 18
Average Estimate - 524 USD 516 USD 2,058 USD 2,181 USD
Year Ago - 496 USD 502 USD 1,978 USD -
Publish Date - 8/12/2025 11/4/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 1,978.21 1,965.31 2,141.52 2,251.66 1,870.35 1,526.42 1,501.85
Change of sales in % 0.66 -8.23 -4.89 20.39 22.53 1.64 5.95
Gross profit on sales 1,252.81 1,222.92 1,370.03 1,432.28 1,211.90 975.29 965.85
Gross profit on sales change in % 2.44 -10.74 -4.35 18.18 24.26 0.98 8.82
Operating income 494.96 445.25 576.23 657.85 537.47 313.67 298.92
Operating income change in % 11.16 -22.73 -12.41 22.40 71.35 4.94 38.88
Income before tax 121.15 429.81 512.60 625.83 439.47 -77.78 225.74
Income before tax change in % -71.81 -16.15 -18.09 42.41 - - 97.37
Income after tax 83.59 341.30 423.21 512.60 359.19 -41.46 190.38
Income after tax change in % -75.51 -19.35 -17.44 42.71 - - 371.31

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 2,122.28 2,307.43 2,821.12 3,050.40 3,114.69 2,699.03 3,113.36
Long-term liabilities per share 7.30 5.58 8.60 7.16 11.63 8.14 10.07
Equity 3,567.34 3,807.76 3,466.61 3,096.55 2,797.84 2,536.59 2,634.97
Equity change in % -6.31 9.84 11.95 10.68 10.30 -3.73 3.70
Balance sheet total 5,689.62 6,115.19 6,287.74 6,146.95 5,912.53 5,235.62 5,748.33
Balance sheet total change in % -6.96 -2.74 2.29 3.96 12.93 -8.92 14.09

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 9.05 9.04 9.87 10.29 8.47 7.14 6.82
P/E ratio (year end quote, basic EPS) 119.71 29.35 27.12 25.16 34.46 - 42.25
P/E ratio (year end quote, diluted EPS) 119.71 29.35 27.12 25.16 34.46 - 42.25
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 62.70 62.27 55.13 50.38 47.32 48.45 45.84
Debt ratio in % 37.30 37.73 44.87 49.62 52.68 51.55 54.16

QIAGEN Dividend Calendar

Date Name Dividend *yield Currency
2024 QIAGEN N.V. 0.00 0.00 USD
2023 QIAGEN N.V. 0.00 0.00 USD
2022 QIAGEN N.V. 0.00 0.00 USD
2021 QIAGEN N.V. 0.00 0.00 USD
2020 QIAGEN N.V. 0.00 0.00 USD
2019 QIAGEN N.V. 0.00 0.00 USD
2018 QIAGEN N.V. 0.00 0.00 USD
2017 QIAGEN N.V. 0.00 0.00 USD
2016 QIAGEN N.V. 0.00 0.00 USD
2015 QIAGEN N.V. 0.00 0.00 USD
2014 QIAGEN N.V. 0.00 0.00 USD
2013 QIAGEN N.V. 0.00 0.00 USD
2012 QIAGEN N.V. 0.00 0.00 USD
2011 QIAGEN N.V. 0.00 0.00 USD
2010 QIAGEN N.V. 0.00 0.00 USD
2009 QIAGEN N.V. 0.00 0.00 USD
*Yield of the Respective Date

QIAGEN Calendar

Event Estimate Info Date
Annual General Meeting 0.381 USD Annual General Meeting 06/26/2025
Earnings Report 0.601 USD Q2 2025 Earnings Release 08/12/2025
Earnings Report 0.583 USD Q3 2025 Earnings Release 11/04/2025
Earnings Report 0.612 USD Q4 2025 Earnings Release 02/10/2026
Earnings Report 0.570 USD Q1 2026 Earnings Release 05/04/2026

QIAGEN Past Events

Event Actual EPS Info Date
Earnings Report 0.410 USD Q1 2025 Earnings Release 05/07/2025
Earnings Report 0.401 USD Q4 2024 Earnings Release 02/05/2025
Earnings Report 0.453 USD Q3 2024 Earnings Release 11/06/2024
Earnings Report -0.854 USD Q2 2024 Earnings Release 07/31/2024
Annual General Meeting 1.569 USD Annual General Meeting 06/21/2024
Earnings Report 0.370 USD Q1 2024 Earnings Release 04/29/2024
Earnings Report 0.445 USD Q4 2023 Earnings Release 02/06/2024
Earnings Report 0.361 USD Q3 2023 Earnings Release 10/30/2023
Earnings Report 0.371 USD Q2 2023 Earnings Release 08/08/2023
Annual General Meeting 1.951 USD Annual General Meeting 06/22/2023
Earnings Report 0.392 USD Q1 2023 Earnings Release 05/03/2023
Earnings Report 0.414 USD Q4 2022 Earnings Release 02/07/2023
Earnings Report 0.382 USD Q3 2022 Earnings Release 11/07/2022
Earnings Report 0.445 USD Q2 2022 Earnings Release 07/27/2022
Annual General Meeting 2.343 USD Annual General Meeting 06/23/2022
Earnings Report 0.711 USD Q1 2022 Earnings Release 04/27/2022
Earnings Report 0.594 USD Q4 2021 Earnings Release 02/08/2022

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

QIAGEN Management

Name Job
Lawrence A. Rosen Chairman-Supervisory Board
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lezette Young Manager-Global Compliance
Eva Pisa Member-Supervisory Board
Eva van Pelt Member-Supervisory Board
Bert van Meurs Member-Supervisory Board
Toralf Haag Member-Supervisory Board
Metin Colpan Member-Supervisory Board
Ross L. Levine Member-Supervisory Board
Elaine R. Mardis Member-Supervisory Board
Elizabeth E. Tallett Member-Supervisory Board
Stephen H. Rusckowski Member-Supervisory Board
Jean-Pascal Viola SVP, Head-Strategy & Business Development
Thomas Theuringer Senior Director-Corporate Communications
Jonathan G. Sheldon Senior VP-Digital Insights Business Area
Antonio Santos Senior Vice President & Head-Global Operations
Stephany Foster Senior Vice President & Head-Human Resources
Philipp von Hugo VP, Head-Global Legal Affairs & Compliance
John Gilardi VP-IR & Head-Corporate Communications